UCL Institute of Cardiovascular Science
- Myocardial disease
- Structural heart disease
- Vascular disease
- Cardiovascular genetics
- Regenerative medicine
- Genetic epidemiology and translational cardiovascular genomics
- Preventions and outcomes
- News & events
- Contact us
Heart failure is a complex syndrome which results from the heart’s inability to pump enough blood to meet the body’s needs. Clinical presentation typically is with shortness of breath, fatigue and signs of fluid retention. The most common cause is myocardial infarction.
Heart failure affects 1 – 2% of the UK population; the incidence and prevalence increase significantly with age, affecting approximately 7% of those aged 75 – 85 years. Overall prognosis and patient quality of life are poor; 14% of newly diagnosed patients die within the first six months, the average life expectancy is approximately 3 years and physical and social limitations for the patient are significant. The expenditure for heart failure is approximately 1 – 2% of the NHS budget, mainly related to costs of hospital based patient management. Our research focuses on outcome measures which assess patient satisfaction and the delivery of specialist care to support heart failure management within the community.
Key research activities
Conventional outcome measures have focused on process and survival rather than ‘patient satisfaction’. Our research on treatments, including palliative care, investigates the impact of patient generated measures of outcome e.g. 6 minute walk, and quality of life.
Our research aims to develop and evaluate the impact (quality, efficacy) of a community focused heart failure service which is integrated with the hospitals provision of care working within the UCL Partners and NC London network structure.
Novel percutaneous treatments for heart failure and associated complications are in development. Our work explores outcomes of a percutaneous device to reduce left ventricular volume and percutaneous Mitraclip technology in patient with heart failure and secondary mitral regurgitation.